Claims
- 1. A method for treating depression in a subject afflicted with such condition comprising administering to the subject a therapeutically effective amount of a compound of the formula I:
- 2. The method of claim 1 wherein the compound of formula I is topiramate.
- 3. The method of claim 1, wherein the therapeutically effective amount is from about 10 to 650 mg daily.
- 4. The method of claim 1, wherein the amount is from about 16 to 325 mg once or twice daily.
- 5. The method of claim 1, wherein the depression is unipolar depression.
- 6. The method of claim 1, wherein the depression is treatment-refractory depression.
- 7. The method of claim 1, wherein the depression is resistant depression.
- 8. The method of claim 1, wherein the depression is anxious depression.
- 9. The method of claim 1, wherein the depression is dysthymia.
- 10. A method for treating depression in a subject afflicted with such condition comprising administering to the subject a therapeutically effective amount of a compound of the formula I
- 11. The method of claim 10 wherein the compound of formula I is administered in combination with one or more compounds selected from the group consisting of imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, maprotiline, amoxapine, trazodone, bupropion, chlomipramine, fluoxetine, citalopram, sertraline, paroxetine, fluvoxamine, nefazadone, venlafaxine, milnacipran, reboxetine, mirtazapine, phenelzine, tranylcypromine, moclobemide, Kava-Kava, St. John's Wart, s-adenosylmethionine, thyrotropin releasing hormone, neurokinin receptor antagonists and triiodothyronine.
- 12. The method of claim 10, wherein the compound of formula I is topiramate.
- 13. The method of claim 10, wherein the therapeutically effective amount is from about 10 to 650 mg daily.
- 14. The method of claim 10, wherein the amount is from about 16 to 325 mg once or twice daily.
- 15. The method of claim 10, wherein the compound of formula I is topiramate and is administered in combination with one or more compounds selected from the group consisting of mono-amine oxidase inhibitors, tricyclics, serotonin reuptake inhibitors, serotonin noradrenergic reuptake inhibitors; noradrenergic and specific serotonergic agents and atypical antidepressants.
- 16. The method of claim 15 wherein the compound of formula I is topiramate and is administered in combination with one or more compounds selected from the group consisting of phenelzine, tranylcypromine, moclobemide, imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline, trimipramine, chlomipramine, amoxapine, fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine, venlafaxine, milnacipran, mirtazapine and bupropion.
- 17. The method of claim 10, wherein the compound of formula I is topiramate and is administered in combination with one or more compounds selected from the group consisting of neuropeptides, compounds targeting neuropeptide receptors and hormones.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. provisional application Serial No. 60/222,489 file Aug. 02, 2000, the contents of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60222489 |
Aug 2000 |
US |